Urgent and clinically significant safety updates for veterinary medicines

Urgent and clinically significant safety updates arising from pharmacovigilance data, including reported adverse events, for veterinary medicines authorised in the UK.

Adverse effects, or adverse events as they are more widely described in veterinary pharmacovigilance, are observations that are unfavourable and unintended that happen after giving a medicine to an animal or after an animal or human are exposed to a medicine. Adverse events might include an unexpected side effect, a medicine not working as well as expected, risk to a person handling a medicine or an environmental impact.

To find out how to report any kind of adverse event following use of an animal medicine, human medicine or unauthorised product please visit: Report a problem with an animal medicine or animal exposed to human medicine - GOV.UK.

The VMD’s pharmacovigilance team continuously monitors all adverse event reports that are submitted to the VMD and reports submitted directly to the Marketing Authorisation Holder (pharmaceutical company responsible for the medicine).

List of urgent and/or clinically significant safety updates

Urgent and/or clinically significant safety updates published by the VMD in the last 12 months.

SPC changes listed on this page may have been made as a result of routine rather than urgent pharmacovigilance processes. They include additions of Medically Important Terms (MITs), however. SPC changes involving non-MITs assessed as having a significant beneficial clinical impact may also be included. More detail can be found in our adverse event reporting guidance for pharmaceutical companies.

Other pharmacovigilance updates from the VMD published in the last 12 months.

To receive updates on this page click on the ‘Get emails about this page’ button at the end of the page.

Further guidance on what veterinary pharmacovigilance is and who is responsible can be found in the  Monitoring the safety of animal medicines guidance.